Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth

Nature Medicine

Volumn 23, Issue 1, 2017, Pages 120-127

  Cramer, Shira L ^a   Saha, Achinto ^b   Liu, Jinyun ^c   Tadi, Surendar ^d   Tiziani, Stefano ^d   Yan, Wupeng ^e   Triplett, Kendra ^a,e   Lamb, Candice ^a,e   Alters, Susan E ^f   Rowlinson, Scott ^f   Zhang, Yan Jessie ^e   Keating, Michael J ^c   Huang, Peng ^c   DiGiovanni, John ^b   Georgiou, George ^a,e   Stone, Everett ^e  

^a The University of Texas at Austin   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d The University of Texas at Austin   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f Aeglea BioTherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CURCUMIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYCLIN E1; CYSTEINASE; CYSTEINE; FLUDARABINE; GLUTATHIONE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TRANSCRIPTION FACTOR E2F4; UNCLASSIFIED DRUG; CYST(E)INASE PROTEIN, HUMAN; CYSTATHIONINE GAMMA LYASE; CYSTINE; MACROGOL DERIVATIVE;

ALLOMETRY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME KINETICS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MEDIAN SURVIVAL TIME; MTT ASSAY; MULTIPLE CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; TUMOR XENOGRAFT; ULTRASTRUCTURE; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; MACACA FASCICULARIS; METABOLISM; MOUSE; OXIDATIVE STRESS; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYSTATHIONINE GAMMA-LYASE; CYSTEINE; CYSTINE; FEMALE; GLUTATHIONE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MACACA FASCICULARIS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OXIDATIVE STRESS; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84996993100     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4232     Document Type: Article

References (59)

1. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8, 579-591 (2009).
2. Dixon, S.J. & Stockwell, B.R. The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10, 9-17 (2014).
3. Harris, I.S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211-222 (2015).
4. Liu, H., Zhi, Y., Geng, G., Yu, Z. & Xu, H. [Effect of phenethyl isothiocyanate given at different duration of gestation on the outcome of pregnancy in rats]. J. Hyg. Res. 40, 283-286 (2011).
5. Reliene, R. & Schiestl, R.H. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis 27, 240-244 (2006).
6. Belalcázar, A.D., Ball, J.G., Frost, L.M., Valentovic, M.A. & Wilkinson, J. IV. Transsulfuration is a signifcant source of sulfur for glutathione production in human mammary epithelial cells. ISRN Biochem. 2013, 637897 (2013).
7. Persa, C., Osmotherly, K., Chao-Wei Chen, K., Moon, S. & Lou, M.F. The distribution of cystathionine β-synthase (CBS) in the eye: implication of the presence of a trans-sulfuration pathway for oxidative stress defense. Exp. Eye Res. 83, 817-823 (2006).
8. Vitvitsky, V., Thomas, M., Ghorpade, A., Gendelman, H.E. & Banerjee, R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 281, 35785-35793 (2006).
9. You, X.-J. et al. Expression of cystathionine β-synthase and cystathionine γ-lyase in human pregnant myometrium and their roles in the control of uterine contractility. PLoS One 6, e23788 (2011).
10. Zhao, H. et al. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer. PLoS One 7, e49683 (2012).
11. Kim, J. et al. Expression of cystathionine p-synthase is downregulated in hepatocellular carcinoma and associated with poor prognosis. Oncol. Rep. 21, 1449-1454 (2009).
12. Timmerman, L.A. et al. Glutamine sensitivity analysis identifes the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24, 853-863 (2013).
13. Takeuchi, S. et al. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas. Neurosurgery 72, 33-41 discussion 41, (2013).
14. Shiozaki, A. et al. xCT, component of cysteine/glutamate transporter, as an independent prognostic factor in human esophageal squamous cell carcinoma. J. Gastroenterol. bok49, 1-11 (2014).
15. Doxsee, D.W. et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67, 162-171 (2007).
16. Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol. 14, 276-286 (2012).
17. Stone, E. et al. De novo engineering of a human cystathionine-y-lyase for systemic L-methionine depletion cancer therapy. ACS Chem. Biol. 7, 1822-1829 (2012).
18. Huang, S. et al. Site-directed mutagenesis on human cystathionine-y-lyase reveals insights into the modulation of H2S production. J. Mol. Biol. 396, 708-718 (2010).
19. Kumar, B., Koul, S., Khandrika, L., Meacham, R.B. & Koul, H.K. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68, 1777-1785 (2008).
20. Afanas'ev, I. Reactive oxygen species signaling in cancer: comparison with aging. Aging Dis. 2, 219-230 (2011).
21. Höll, M. et al. ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells. Mol. Carcinog. 55, 27-39 (2016).
22. high prostate cancer cells derived from the Hi-Myc mouse model are tumor-initiating cells with basal-epithelial characteristics and differentiation potential in vitro and in vivo. Oncotarget 7, 25194-25207 (2016).
23. Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223-238 (2003).
24. Cardaci, S., Filomeni, G. & Ciriolo, M.R. Redox implications of AMPK-mediated signal transduction beyond energetic clues. J. Cell Sci. 125, 2115-2125 (2012).
25. 2+/calmodulin-dependent kinase kinase-p (CaMKK-p). J. Biol. Chem. 287, 38625-38636 (2012).
26. Mungai, P.T. et al. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol. Cell. Biol. 31, 3531-3545 (2011).
27. Liang, J. et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 9, 218-224 (2007).
28. Jones, R.G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293 (2005).
29. Foye, W., Lemke, T. & Williams, D. Foye's Principles of Medicinal Chemistry 2007 (Lippincott Williams & Wilkins, 2007).
30. West, G.B. & Brown, J.H. The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J. Exp. Biol. 208, 1575-1592 (2005).
31. Lewerenz, J. et al. The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 18, 522-555 (2013).
32. Kato, S., Ishita, S., Sugawara, K. & Mawatari, K. Cystine/glutamate antiporter expression in retinal Müller glial cells: implications for DL-alpha-aminoadipate toxicity. Neuroscience 57, 473-482 (1993).
33. Narang, V.S., Pauletti, G.M., Gout, P.W., Buckley, D.J. & Buckley, A.R. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res. 23, 4571-4579 (2003).
34. Fang, J., Lu, J. & Holmgren, A. Thioredoxin reductase is irreversibly modifed by curcumin: a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280, 25284-25290 (2005).
35. Kanai, M. et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 71, 1521-1530 (2013).
36. Carroll, R.E. et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev. Res. (Phila.) 4, 354-364 (2011).
37. Kanai, M. et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother. Pharmacol. 68, 157-164 (2011).
38. Liu, J. et al. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells. Leukemia 28, 118-128 (2014).
39. Olsen, L.F., Issinger, O.-G. & Guerra, B. The yin and yang of redox regulation. Redox Rep. 18, 245-252 (2013).
40. Vousden, K.H. & Ryan, K.M. p53 and metabolism. Nat. Rev. Cancer 9, 691-700 (2009).
41. Zhang, W. et al. Expression profling of homocysteine junction enzymes in the NCI60 panel of human cancer cell lines. Cancer Res. 65, 1554-1560 (2005).
42. Mandal, P.K. et al. System x(c)-and thioredoxin reductase 1 cooperatively rescue glutathione defciency. J. Biol. Chem. 285, 22244-22253 (2010).
43. Pader, I. et al. Thioredoxin-related protein of 14 kDa is an effcient l-cystine reductase and S-denitrosylase. Proc. Natl. Acad. Sci. USA 111, 6964-6969 (2014).
44. Trachootham, D. et al. Effective elimination of fudarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112, 1912-1922 (2008).
45. Zhang, W. et al. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms. Mol. Med. Rep. 12, 7374-7388 (2015).
46. Lee, W.-J. et al. Nonautophagic cytoplasmic vacuolation death induction in human PC-3M prostate cancer by curcumin through reactive oxygen species-mediated endoplasmic reticulum stress. Sci. Rep. 5, 10420 (2015).
47. Sánchez, Y., Simón, G.P., Calviño, E., de Blas, E. & Aller, P. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines. J. Pharmacol. Exp. Ther. 335, 114-123 (2010).
48. Chaiswing, L., Zhong, W., Liang, Y., Jones, D.P. & Oberley, T.D. Regulation of prostate cancer cell invasion by modulation of extra-and intracellular redox balance. Free Radic. Biol. Med. 52, 452-461 (2012).
49. Minor, W. & Otwinowski, Z. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
50. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Cryst. 40, 658-674 (2007).
51. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
52. DeLano, W.L. The PyMOL molecular graphics system (Schrödinger LLC, 2002).
53. Cheson, B.D. et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am. J. Hematol. 29, 152-163 (1988).
54. Huang, P., Sandoval, A., Van Den Neste, E., Keating, M.J. & Plunkett, W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fudarabine. Leukemia 14, 1405-1413 (2000).
55. Pelicano, H. et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 278, 37832-37839 (2003).
56. Tiziani, S. et al. Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal. Biochem. 377, 16-23 (2008).
57. Okuda, S. et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res. 36, W423-W426 (2008).
58. Wishart, D.S. et al. HMDB: the human metabolome database. Nucleic Acids Res. 35, D521-D526 (2007).
59. Sana, T.R., Roark, J.C., Li, X., Waddell, K. & Fischer, S.M. Molecular formula and METLIN Personal Metabolite Database matching applied to the identifcation of compounds generated by LC/TOF-MS. J Biomol Tech 19, 258-266 (2008).